Cognition and the course of prodromal Parkinson's disease

Prospective data on cognition in prodromal Parkinson's disease are limited. The objectives of this study were to assess in prodromal PD (1) if baseline cognition predicts conversion to clinical PD, (2) if baseline dopamine transporter binding predicts longitudinal changes in cognition, and (3) if impaired olfaction predicts future cognitive decline.

[1]  D. Jennings,et al.  Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort , 2017, JAMA neurology.

[2]  Albert Hofman,et al.  Trajectories of prediagnostic functioning in Parkinson’s disease , 2017, Brain : a journal of neurology.

[3]  L. Wilkins.  Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease , 2016, Neurology.

[4]  Xuemei Huang,et al.  Serum 25‐hydroxyvitamin D concentrations in Mid‐adulthood and Parkinson's disease risk , 2016, Movement disorders : official journal of the Movement Disorder Society.

[5]  J. Toledo,et al.  Olfactory impairment predicts cognitive decline in early Parkinson's disease. , 2016, Parkinsonism & related disorders.

[6]  D. Jennings,et al.  Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings , 2016, Movement disorders : official journal of the Movement Disorder Society.

[7]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[8]  Roger L Albin,et al.  Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study , 2015, Neurology.

[9]  D. Aarsland,et al.  Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[10]  Masayuki Matsumoto.  Dopamine signals and physiological origin of cognitive dysfunction in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[11]  J. Haines,et al.  Vitamin D from different sources is inversely associated with Parkinson disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[12]  D. Aarsland,et al.  Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.

[13]  Y. Lee,et al.  Vitamin D receptor polymorphisms and susceptibility to Parkinson’s disease and Alzheimer’s disease: a meta-analysis , 2014, Neurological Sciences.

[14]  A. Lang,et al.  Longitudinal follow-up of SWEDD subjects in the PRECEPT Study , 2014, Neurology.

[15]  R. Mehanna.  Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study , 2014, Neurology.

[16]  Ralph H. B. Benedict,et al.  Hopkins Verbal Learning Test--Revised , 2013 .

[17]  Liang Shen,et al.  Vitamin D levels in Alzheimer's and Parkinson's diseases: a meta-analysis. , 2013, Nutrition.

[18]  Gary Aston-Jones,et al.  The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease , 2012, Front. Behav. Neurosci..

[19]  J. Gagnon,et al.  Cognition in Rapid Eye Movement Sleep Behavior Disorder , 2012, Front. Neur..

[20]  Danna Jennings,et al.  Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study , 2012, Movement disorders : official journal of the Movement Disorder Society.

[21]  S. Cappa,et al.  Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder. , 2011, Sleep.

[22]  P. Knekt,et al.  Serum vitamin D and the risk of Parkinson disease. , 2010, Archives of neurology.

[23]  H. Berendse,et al.  Hyposmia and executive dysfunction as predictors of future Parkinson's disease: A prospective study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[24]  D. Aarsland,et al.  Cognitive impairment in incident, untreated Parkinson disease , 2009, Neurology.

[25]  M. Delong,et al.  Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. , 2008, Archives of neurology.

[26]  A. Mackay-Sim,et al.  Behavioural characterization of Vitamin D receptor knockout mice , 2005, Behavioural Brain Research.

[27]  C. Tanner,et al.  Parkinsonian signs and substantia nigra neuron density in decendents elders without PD , 2004, Annals of neurology.

[28]  David Oakes,et al.  (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. , 2004, Archives of neurology.

[29]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[30]  S. Kikuchi,et al.  Effect of 1,25‐dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L‐buthionine sulfoximine and 1‐methyl‐4‐phenylpyridine , 2000, Journal of neuroscience research.

[31]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[32]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[33]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[34]  R. Doty,et al.  Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory function , 1984, Physiology & Behavior.

[35]  G. Jones.  Assay of vitamins D2 and D3, and 25-hydroxyvitamins D2 and D3 in human plasma by high-performance liquid chromatography. , 1978, Clinical chemistry.

[36]  Philip Schatz,et al.  Repeatable Battery for the Assessment of Neuropsychological Status , 2018 .

[37]  Pars Investigators.  Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings , 2016 .

[38]  J. Seibyl,et al.  Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[39]  J. Y. Wang,et al.  Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. , 2001, Brain research.

[40]  O. Spreen,et al.  A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary , 1991 .